- Home
- SITC vs NERV Comparison
SITC vs NERV Comparison
Compare SITC & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SITC | NERV |
|---|---|---|
| Founded | 1965 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.8M | 166.4M |
| IPO Year | 1994 | 2014 |
Fundamental Metrics
Financial Performance| Metric | SITC | NERV |
|---|---|---|
| Price | $3.33 | $3.33 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.33 |
| AVG Volume (30 Days) | ★ 1.2M | 116.0K |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | ★ 92.59% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $123,649,000.00 | $41,175,600.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.80 | $2.24 |
| 52 Week High | $8.95 | $12.46 |
Technical Indicators
Market Signals| Indicator | SITC | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 59.48 | 33.73 |
| Support Level | $2.86 | N/A |
| Resistance Level | $4.55 | $4.73 |
| Average True Range (ATR) | 0.11 | 0.24 |
| MACD | 0.07 | -0.02 |
| Stochastic Oscillator | 69.78 | 18.31 |
Price Performance
Historical ComparisonAbout SITC SITE Centers Corp.
SITE Centers Corp is a self-administered and self-managed REIT that operates as a fully integrated real estate company. The company is engaged in the business of owning, leasing, acquiring, redeveloping, developing, and managing shopping centers.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.